Alzheimer s & Dementia
December 1, 2025
Danielle Bukovsky, Aron Amaev, Jianmeng Song et al.
Abstract Background Amnestic mild cognitive impairment (aMCI) is characterized by synaptic loss and cognitive decline and is considered a precursor to Alzheimer’s Disease. Currently, there are no effective treatments for aMCI, and available treatments (i.e., cholinesterase inhibitors) do not appear to improve cognitive or functional outcomes. Psychedelics, including psilocybin, have regained...
Alzheimer s & Dementia
December 1, 2025
Leelavathi N. Madhu, Yogish Somayaji, Sanya Kotian et al.
Abstract Background Chronic neuroinflammation plays a significant role in Alzheimer’s disease (AD) pathogenesis associated with a decline in cognitive and mood function. Currently, there are no effective therapies to alleviate the progression of brain dysfunction in AD. Psilocybin, an FDA‐approved drug for treating major depressive disorder, can restrain neuroinflammation and improve...
Alzheimer s & Dementia
December 1, 2025
Anjali Rose Friedman
Abstract Background Recent studies have highlighted the neuroprotective properties of certain mushrooms. Proposing a research hypothesis for a novel field of study into mitigating the neurological and neuropsychological symptoms associated with Alzheimer's disease (AD) and possible cure with natural methods. Psilocybe cubensis and Hericium erinaceus have proven to show therapeutic effects for...
Alzheimer s & Dementia
December 1, 2025
Darren M. Lipnicki, Meritxell Valenti, Elizabeth Lucia Valeriano‐Lorenzo et al.
Abstract Background Evidence suggests that dreaming is subserved by the default mode network (DMN) (Domhoff, 2022. The Neurocognitive Theory of Dreaming ). β‐amyloid plaques and phosphorylated tau ( p ‐tau) protein tangles accumulate and contribute to abnormal functionality in the DMN long before clinical Alzheimer's disease, and similarly early abnormal DMN functionality is shown by...
Alzheimer s & Dementia
December 1, 2024
Jitendra Kumar Sinha, Shampa Ghosh, Krishna Kumar Singh et al.
1 citation
Abstract Background Traditionally associated with recreational and spiritual uses, psychedelics have gained attention in psychotherapy for their therapeutic potential. Functioning as potent 5‐hydroxytryptamine (5HT) agonists, these compounds have demonstrated the ability to enhance neural plasticity by activating serotoninergic and glutamatergic systems. Despite these recognized effects, their...
Alzheimer s & Dementia
December 1, 2020
Tim Whitfield, Thorsten Barnhofer, Rebecca L. Acabchuk et al.
6 citations
Abstract Background The primary focus of mindfulness‐based program (MBP) research to date has been on mental health. More recently, attention has turned to putative effects on cognition. An evidence synthesis is required to answer the key question of ‘Do MBPs confer cognitive benefit, and if so, for whom?’ A particularly crucial distinction is whether benefits differ according to individuals’...
Alzheimer s & Dementia
July 1, 2011
Lap Ho, Patricia A. Bloom, Joan Griffiths Vega et al.
4 citations
Numerous studies have documented that caregiving for a dementia patient may be associated with increased risk of emotional distress, depression, dementia, physical health problems, and death. Other studies suggest that targeting caregivers as the recipients of interventions may greatly improve Alzheimer's care, leading to reduced behavioral symptoms and increased length of time that the...
Alzheimer s & Dementia
July 1, 2011
Márcio Luiz Figueredo Balthazar, Tátila Martins Lopes, Ana Carolina Coan et al.
Dysfunction of brain's Default Mode Network (DMN) has been increasingly described in patients with neurodegenerative diseases, but little is known about DMN's intrinsic functional connectivity (IFC) in Posterior Cortical Dysfunction (PCD) syndrome. We report a 56 year-old woman with PCD syndrome (MMSE = 24, CDR = 0.5) with visuospatial and anxiety complaints, confirmed by neuropsychological...